Journal of Pharmaceutical Health Care and Sciences最新文献

{"title":"Preservation of eGFRcre for 1 year with HIF-PHI in non-dialysis patients: a retrospective observational cohort study.","authors":"Tomohiro Aigami, Tomoyuki Ishigo, Mai Miyao, Masatoshi Nonoyama, Tomohisa Yamashita, Masayuki Koyama, Satoshi Fujii, Toshiyuki Yano, Masato Furuhashi, Masahide Fukudo, Takaki Toda","doi":"10.1186/s40780-025-00527-1","DOIUrl":"10.1186/s40780-025-00527-1","url":null,"abstract":"<p><p>BACKGROUND: Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) effectively increase hemoglobin levels to treat anemia in patients with chronic kidney disease (CKD). However, there is a paucity of studies on the effect of HIF-PHIs on renal outcomes, such as estimated glomerular filtration rate based on serum creatinine (eGFRcre). Therefore, this study aimed to examine the trajectory of eGFRcre decline following initiation of treatment with HIF-PHI and erythropoiesis-stimulating agents (ESAs) in non-dialysis patients. METHODS: This single-center, retrospective study enrolled non-dialysis patients who were prescribed HIF-PHIs between January 1, 2020 and December 31, 2022. We used five HIF-PHIs approved in Japan. The eGFRcre slope for a year after HIF-PHIs therapy was initiated was compared with that of ESAs. The eGFRcre slope was calculated using a linear mixed-effects model for repeated measures over a year from the time of enrollment. RESULTS: This study included 134 patients: 79 and 55 patients treated with HIF-PHIs and ESAs, respectively. The model adjusting for time, drug (HIF-PHI or ESA), their interaction, age, sex, BMI, and CKD stage showed that the effect on eGFRcre differed between HIF-PHIs and ESAs (−2.11 ± 0.57 mL/min/1.73 m2 per year vs. −3.27 ± 0.17 mL/min/1.73 m2 per year, p = 0.046). Subgroup analysis by CKD stage revealed a difference in the eGFRcre slope between HIF-PHI and ESA only in the stage 4 group (−1.89 ± 0.44 mL/min/1.73 m2 per year vs. −3.69 ± 0.44 mL/min/1.73 m2 per year, p < 0.001). CONCLUSIONS: HIF-PHI preserved eGFRcre for a year, suggesting that its effect was superior to that of ESA. </p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":"10"},"PeriodicalIF":1.3,"publicationDate":"2025-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12838504/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145800559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of intake pattern of SGLT2 inhibitors among shift workers with diabetes: a crossover study.","authors":"Aya Torii-Goto, Kazumi Shiomi, Masatoshi Murase, Hiroki Yoshioka, Junko Ito, Masae Yoshikawa","doi":"10.1186/s40780-025-00517-3","DOIUrl":"10.1186/s40780-025-00517-3","url":null,"abstract":"<p><strong>Background: </strong>Shift workers experience regular changes in their waking hours due to fluctuating work schedules. The timing of their medication intake differs depending on whether they are working a day or night shift. Sodium-glucose co-transporter 2 (SGLT2) inhibitors are prescribed once a day and are often taken before or after breakfast. However, studies on the optimal dosing times for the effective treatment of shift workers are lacking. In this study, we investigated whether the effects were different by the pattern of SGLT2 inhibitor intake for shift workers with diabetes.</p><p><strong>Methods: </strong>Seven shift workers with diabetes who were taking an SGLT2 inhibitor were analyzed. All participants took the medication upon waking for 14 days, followed by administration at a fixed time for another 14 days. Glucose levels were measured over 14 days when the drug was administered either upon waking or at a fixed time of day. The time in range (TIR), which indicates the percentage of time during which the glucose level is within the range of 70-180 mg/dL, was used as the main evaluation index.</p><p><strong>Results: </strong>The mean HbA1c of the participants was 7.1%. The TIR was 88.5% in the administration upon waking group and 84.9% in the administration at a fixed time group. No significant difference in TIR values was observed between the two administration groups.</p><p><strong>Conclusion: </strong>A TIR of 70% or higher is recommended to prevent the onset of diabetic complications. Consistent intake of SGLT2 inhibitors, regardless of whether it is during the day or night shift, may help stabilize blood glucose levels in shift workers throughout the day and night, thereby preventing the development of complications.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"11 1","pages":"108"},"PeriodicalIF":1.2,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12713290/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145781377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Isosakuranetin ameliorates hypertension in rats induced by L-NAME.","authors":"Rungusa Pantan, Ratchanaporn Chokchaisiri, Apichart Suksamrarn, Chainarong Tocharus","doi":"10.1186/s40780-025-00529-z","DOIUrl":"10.1186/s40780-025-00529-z","url":null,"abstract":"<p><strong>Background: </strong>Hypertension is a major global health problem that often develops without noticeable symptoms. Current treatments and complementary approaches focus on improving endothelial function and enhancing nitric oxide (NO) production to promote vasodilation and lower blood pressure. Isosakuranetin, a flavanone found in Chromolaena odorata leaves, has shown potential antihypertensive properties. This study aimed to investigate the effects of isosakuranetin on L-N^G-Nitroarginine methyl ester (L-NAME)-induced hypertension, focusing on its ability to enhance NO production and reduce oxidative stress.</p><p><strong>Methods: </strong>This study investigated the antihypertensive effects of the flavanone isosakuranetin in male Wistar rats (n = 8 per group). Hypertension was induced by L-NAME, a nitric oxide synthase inhibitor, for four weeks, followed by treatment with isosakuranetin (10, 20, or 40 mg/kg) or enalapril (10 mg/kg) for an additional two weeks. Systolic blood pressure (SBP), heart rate, and body weight were monitored weekly. After six weeks, the effects of isosakuranetin on NO level and oxidative stress were assessed using the Griess reaction, 2',7'-dichlorofluorescein diacetate (DCF-DA), and superoxide dismutase (SOD) activity assays.</p><p><strong>Results: </strong>The results demonstrated that the SBP was significantly reduced in the isosakuranetin treatment group when compared to the hypertensive group. Additionally, isosakuranetin treatment significantly restored plasma nitrate/nitrite levels and showed the potential to reduced oxidative stress, as indicated by the decrease in reactive oxygen species (ROS) levels and a significant increase in SOD activity.</p><p><strong>Conclusion: </strong>These findings suggest that isosakuranetin is a promising natural compound for managing hypertension, demonstrating its potential for clinical application.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":"8"},"PeriodicalIF":1.2,"publicationDate":"2025-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12821859/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145774890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of an antimicrobial stewardship program using an automated antimicrobial surveillance system based on indication for antimicrobial administration.","authors":"Mikiyasu Sakai, Takamasa Sakai, Toshitaka Watariguchi, Atsushi Kawabata, Mana Shirai, Mitsumi Kakimoto, Yuki Hirao, Fumiko Ohtsu","doi":"10.1186/s40780-025-00528-0","DOIUrl":"10.1186/s40780-025-00528-0","url":null,"abstract":"<p><p>BACKGROUND: Conventional antimicrobial surveillance measures usage in days of therapy (DOT). However, assessments using DOT alone often ignore indication-specific details, which limits the identification of targets for antimicrobial stewardship (AS) interventions. Therefore, we have developed an automated surveillance system (the Antimicrobial and Patient Background Surveillance System [APBSS]) in order to analyze antimicrobial use based on indications, and evaluated the short-term effectiveness of an AS program using APBSS surveillance data, as an initial evaluation of the newly developed system. METHODS: Using an interrupted time series design, we calculated the carbapenem DOT per 100 patient days as the primary outcome by comparing the pre-intervention (October 2022 to September 2024) and post-intervention (October 2024 to September 2025) periods. During the intervention, the AS team presented the APBSS surveillance data, including indication-specific antimicrobial use, patient characteristics, annual trends at our hospital, and multicenter comparisons. The antipseudomonal agent DOT was a secondary outcome. RESULTS: Patient characteristics did not differ substantially between the periods. APBSS surveillance data identified key issues, including high carbapenem use in specific infections (e.g. Gram-negative rod bacteremia), which occurred despite the lower proportion of patients with hematological malignancies compared with other hospitals. However, the intervention significantly reduced carbapenem DOT levels (level change: −0.69/100 patient days, p = 0.017). The antipseudomonal agent DOT also significantly decreased (level change: −1.7/100 patient days, p = 0.004). CONCLUSIONS: The AS program that used APBSS surveillance data improved the use of carbapenems and antipseudomonal agents in the short-term. Thus, our initial evaluation has suggested that AS programs that use APBSS surveillance data can contribute to the appropriate use of antimicrobial agents. </p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":"9"},"PeriodicalIF":1.3,"publicationDate":"2025-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12821170/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145774927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A questionnaire survey of healthcare access and dietary habits in a rural Japanese community: implications for potential community pharmacy roles.","authors":"Hayato Kizaki, Maho Tsukamoto, Mari Yamada, Sana Ito, Megumi Sasaki, Kentaro Sakamoto, Yuki Ikeda, Koji Miyamoto, Haru Iino, Satoko Hori","doi":"10.1186/s40780-025-00524-4","DOIUrl":"10.1186/s40780-025-00524-4","url":null,"abstract":"<p><p>BACKGROUND: Residents in rural mountainous areas face significant challenges in accessing healthcare and food resources, affecting their dietary intake, nutritional status, and overall health. However, detailed evidence on the interplay between access limitations, dietary habits, and nutritional status is limited, hindering the development of effective, equity-focused interventions. This study aimed to evaluate healthcare access, food procurement practices, and dietary intake in such a community to identify key challenges and opportunities for sustainable health support. METHODS: A cross-sectional survey was conducted targeting residents aged ≥ 20 years in a rural Japanese village. Two questionnaires were administered: a food frequency questionnaire based on food groups (FFQg) and a questionnaire we developed that assessed healthcare utilization and food procurement. Macronutrient balance was considered optimal when the intake ratios of the three macronutrients were within the recommended ranges (proteins: 13–20%, fats: 20–30%, carbohydrates: 50–65%). RESULTS: Of 115 respondents (58 males, 57 females), 51.3% shopped for food weekly, with 65.5% requiring 1–2 h of one-way travel time to reach stores. While 86.0% had annual health checkups, only 56.1% received regular dental checkups. Only 25.2% achieved an optimal macronutrient balance for all three macronutrients. Among respondents with hypertension (28.3%), the mean salt intake was 11.3 g, which was higher than that of non-hypertensive residents (p < 0.05). A significant correlation was observed between poor chewing ability and lower subjective health status (p < 0.05). CONCLUSIONS: Residents in this rural mountainous community face significant challenges in healthcare and food access, which are linked to suboptimal dietary intake and health issues. These findings highlight the need to develop community-based health-support systems that can provide targeted nutritional support and health counseling. In the Japanese context, the health-support functions of community pharmacies represent one potential resource that could be leveraged for this purpose, but further research is needed to determine how such services can be effectively implemented to help mitigate health disparities in underserved populations. </p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":"7"},"PeriodicalIF":1.3,"publicationDate":"2025-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12821789/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145751809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors associated with the effectiveness of opioids for dyspnea in hospitalized patients with heart failure: a retrospective, multicenter, observational study.","authors":"Shoichi Yoshikai, Yasushi Moriya, Tomoyuki Yamada, Junichi Higuchi, Emi Goto, Masami Nishihara, Akira Ashida, Kenji Ikeda","doi":"10.1186/s40780-025-00523-5","DOIUrl":"10.1186/s40780-025-00523-5","url":null,"abstract":"<p><p>BACKGROUND: The decision to administer opioids for dyspnea caused by heart failure should be made on an individual basis. However, factors associated with the effectiveness of opioids remain unclear, and information that could guide this decision is lacking. This study aimed to explore factors associated with the effectiveness of opioids to relieve dyspnea caused by heart failure. METHODS: This retrospective, multicenter, observational study included patients 18 years of age or older at the time of admission who received opioid administration (morphine, oxycodone, or hydromorphone) for dyspnea relief but did not receive invasive ventilatory support during hospitalization. Data were collected from the medical records. RESULTS: A total of 129 cases (30 ineffective cases, 80 effective cases, and 19 cases with missing dyspnea assessment data) were collected. The multivariable logistic regression analysis results indicated that the odds ratios of the New York Heart Association classification, number of diuretics used, and oxygen flow rate associated with the presence or absence of dyspnea improvement attributable to opioid administration were 0.496 (95% confidence interval, 0.254–0.967), 1.506 (95% confidence interval, 1.131–2.007), and 0.974 (95% confidence interval, 0.923–1.027), respectively. Trends in odds ratios for both the number of diuretics used and New York Heart Association classification were preserved in the multivariable logistic regression model that included factors that potentially influence dyspnea (p < 0.05). CONCLUSION: The effectiveness of opioids for relieving dyspnea caused by heart failure in hospitalized patients was positively associated with the number of diuretics used and negatively associated with the New York Heart Association classification. </p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":"6"},"PeriodicalIF":1.3,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12802230/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145714671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Publisher Correction: A case of hepatitis B virus reactivation after elranatamab therapy in a patient with multiple myeloma.","authors":"Naoaki Nishimura, Hajime Nakashima, Kenji Yoshikuni, Akihiko Numata, Ryosuke Ogawa","doi":"10.1186/s40780-025-00520-8","DOIUrl":"10.1186/s40780-025-00520-8","url":null,"abstract":"","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"11 1","pages":"107"},"PeriodicalIF":1.2,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12687526/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145714617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A survey on the awareness of a sleep-medication formulary in community health care and its influence on prescribing behavior.","authors":"Akira Ishikawa, Ryosuke Mizumura, Satoru Utsunomiya, Moriyuki Ito, Yohei Kawasaki, Yuki Shiko, Maiko Osawa, Hideki Makabe, Koji Matsuo","doi":"10.1186/s40780-025-00521-7","DOIUrl":"10.1186/s40780-025-00521-7","url":null,"abstract":"<p><strong>Background: </strong>Despite the increasing emphasis on safe prescribing, the impact of local formularies on physician behavior remains underexplored in community healthcare settings. To promote safer pharmacological practices, our institution implemented a hospital-originated sleep-medication formulary in January 2022, which was subsequently disseminated to other local medical institutions in early 2023. This study assessed physicians' awareness of this sleep-medication formulary, and its influence on prescribing behavior in local community healthcare settings.</p><p><strong>Methods: </strong>A questionnaire survey was distributed via a regional medical-cooperation newsletter and responses were received from 84 physicians.</p><p><strong>Results: </strong>Of the 84 physicians, 18% were aware of the formulary. Physicians in the awareness group were more likely to prescribe the recommended medications, particularly orexin receptor antagonists, and reported significantly less difficulty in initiating hypnotic therapy. Logistic regression analysis revealed a significant association between formulary awareness and reduced difficulty in prescribing a suitable hypnotic (odds ratio: 0.24; 95% CI: 0.073-0.78).</p><p><strong>Conclusions: </strong>Local formularies may serve as valuable tools in clinical decision-making and promote safer and more consistent prescribing practices. Strategies such as physician education, concise formulary reference sheets or physician-oriented pocket references, and the development of patient-friendly information materials are warranted to support broader implementation.</p><p><strong>Trial registration: </strong>Not applicable.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":"3"},"PeriodicalIF":1.2,"publicationDate":"2025-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12797493/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145708051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unbeneficial effects of not prescribing antibiotics to pediatric patients with acute upper respiratory infection: a descriptive epidemiological study based on a large Japanese medical claim database.","authors":"Kanako Mizuno, Ryo Inose, Yuichi Muraki","doi":"10.1186/s40780-025-00519-1","DOIUrl":"10.1186/s40780-025-00519-1","url":null,"abstract":"<p><strong>Background: </strong>National Action Plan on Antimicrobial Resistance in Japan recommends further strengthening of antimicrobial stewardship (AS) for acute upper respiratory infection (URI) in outpatients. AS initiatives for outpatients include the establishment of an AS implementation fee that can be claimed when a physician does not prescribe antibiotics to a pediatric patient diagnosed with acute URI that does not require antibiotics, after providing sufficient explanation. However, in Japan, unbeneficial effects of not prescribing antibiotics for acute URIs have not been clarified. This study aimed to investigate whether there were any unbeneficial effects in pediatric patients with acute URIs who claimed the AS implementation fee and were not prescribed antibiotics using a large Japanese medical insurance claim database.</p><p><strong>Methods: </strong>This study used a large Japanese medical insurance claim database provided by IQVIA Japan. Patients aged less than six years of age and with a definitive diagnosis of acute URI and who claimed the AS implementation fee from January 2019 to December 2021 were selected. Among these patients, those with prescriptions other than antibiotics on the date of the first definitive diagnosis of acute URI were included in this study. The prescription of medicines and hospitalization within 10 days of the date of the first definitive diagnosis of acute URI in the target patients were investigated.</p><p><strong>Results: </strong>There were 967,546 patients with a definitive diagnosis of acute URI in the outpatient. Of these, 32,489 patients below six years of age who claimed the AS implementation fee for children were prescribed medications other than antibiotics were considered the target patients for this study. Of these, 12,101 (37.2%) were again prescribed drugs in the outpatient clinic within 10 days, and 2,275 (7.0%) were prescribed antibiotics. The median (interquartile range) number of days until antibiotics were prescribed was 4 (2-7). Additionally, 105 patients (0.3%) were hospitalized within 10 days.</p><p><strong>Conclusion: </strong>This study revealed that there may be at least one risk factor in patients with acute URIs who were not prescribed antibiotics. In case of acute URI diagnosis and absence of antibiotic prescription, patients should be warned of worsening symptoms for at least 4 days.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":"4"},"PeriodicalIF":1.2,"publicationDate":"2025-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12797695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145708034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disproportionality analysis of adverse events in advanced lung cancer treated with atezolizumab plus platinum-based combination chemotherapy.","authors":"Katsuyuki Hazama, Toru Imai, Naohiro Tochikura, Shinsaku Washinosu, Susumu Ootsuka, Kazuhiko Hanada","doi":"10.1186/s40780-025-00522-6","DOIUrl":"10.1186/s40780-025-00522-6","url":null,"abstract":"<p><strong>Background: </strong>Advanced non-squamous non-small cell lung cancer has a poor prognosis, and immune checkpoint inhibitors (ICIs) plus platinum-based combination chemotherapy is the first-line treatment. Atezolizumab, an ICI, has three regimens: atezolizumab + carboplatin (CBDCA) + paclitaxel + bevacizumab [ABCP], atezolizumab + CBDCA + nab-paclitaxel (nab-PTX) [A + CnP], and atezolizumab + CBDCA + pemetrexed [A + CbP]. However, clinical trials directly comparing these regimens have not been reported, and the differences in adverse events have not been fully clarified.</p><p><strong>Methods: </strong>We calculated the reporting odds ratio (ROR), a measure of adverse drug reaction (ADR) signals, using the FDA Adverse Event Reporting System (FAERS) to compare the major ADRs of ABCP, A + CnP, and A + CbP regimens.</p><p><strong>Results: </strong>The ROR (95% confidence interval [CI]) for rash and hypersensitivity-related adverse events was 2.06 (1.81-2.34) for ABCP, 0.81 (0.42-1.56) for A + CnP, and 0.57 (0.37-0.87) for A + CbP; the signal was only detected for the ABCP regimen. In acute kidney injury (AKI), it was ABCP: 1.24 (0.89-1.73), A + CnP: 1.16 (0.37-3.60), and A + CbP: 1.76 (1.06-2.93), and signal was detected only for the A + CbP regimen. Contrarily, signals were detected for colitis, drug-induced liver injury, and pneumonitis for all regimens.</p><p><strong>Conclusions: </strong>Rash and hypersensitivity-related adverse events and AKI were more frequently reported with the ABCP and A + CbP regimens, respectively. These observations may help generate hypotheses regarding regimen-specific adverse event profiles and support future studies toward individualized chemotherapy.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":"2"},"PeriodicalIF":1.2,"publicationDate":"2025-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12797384/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145695886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}